We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

172 hedge funds and large institutions have $2.79B invested in Ultragenyx Pharmaceutical in 2016 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 56 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $6.15M

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

54% more capital invested

Capital invested by funds: $1.81B → $2.79B (+$978M)

20% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 56

7% more funds holding

Funds holding: 161 → 172 (+11)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
172
Holders Change
+11
Holders Change %
+6.83%
% of All Funds
4.59%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
27
Increased
67
Reduced
56
Closed
15
Calls
$14.3M
Puts
$6.15M
Net Calls
+$8.14M
Net Calls Change
+$9.02M

Top Buyers

1
CGT
Capital Guardian Trust
California
+$31.5M
2
Capital International Investors
Capital International Investors
California
+$30.7M
3
CWAM
Columbia Wanger Asset Management
Illinois
+$25.1M
4
EA
Emerald Advisers
Pennsylvania
+$17.2M
5
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$16.9M

Top Sellers

1
Wells Fargo
Wells Fargo
California
-$39.1M
2
Millennium Management
Millennium Management
New York
-$28.8M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$11.5M
4
Ameriprise
Ameriprise
Minnesota
-$11.2M
5
WC
Weatherbie Capital
Massachusetts
-$6.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
TD Asset Management
76
TD Asset Management
Ontario, Canada
$2.74M +$345K +5,409 +16%
CII
77
Capital International Inc
California
$2.5M +$2.25M +35,200 New
Barclays
78
Barclays
United Kingdom
$2.48M +$2.08M +32,566 +1,315%
OM
79
Opaleye Management
Massachusetts
$2.48M -$1.91M -30,000 -46%
USAA
80
United Services Automobile Association
Texas
$2.44M -$5.11K -80 -0.2%
MOACM
81
Mutual of America Capital Management
New York
$2.39M – – –
DekaBank Deutsche Girozentrale
82
DekaBank Deutsche Girozentrale
Germany
$2.38M -$1.6M -25,000 -42%
UBS Group
83
UBS Group
Switzerland
$2.13M +$199K +3,120 +12%
ProShare Advisors
84
ProShare Advisors
Maryland
$2.09M -$329K -5,151 -15%
PPA
85
Parametric Portfolio Associates
Washington
$2M +$346K +5,421 +24%
MLICM
86
Metropolitan Life Insurance Company (MetLife)
New York
$1.82M -$137K -2,148 -8%
Lazard Asset Management
87
Lazard Asset Management
New York
$1.75M – – –
Manulife (Manufacturers Life Insurance)
88
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.74M +$4.47K +70 +0.3%
State Board of Administration of Florida Retirement System
89
State Board of Administration of Florida Retirement System
Florida
$1.73M -$1.28K -20 -0.1%
BG
90
BlackRock Group
United Kingdom
$1.67M +$43.1K +676 +3%
PCM
91
Palisade Capital Management
New Jersey
$1.53M -$201K -3,151 -13%
WMSA
92
Weiss Multi-Strategy Advisers
New York
$1.52M -$23.6K -370 -2%
UBS AM
93
UBS AM
Illinois
$1.51M +$106K +1,660 +8%
N
94
Nuveen
North Carolina
$1.47M -$121K -1,896 -8%
AIG
95
American International Group
New York
$1.47M +$1.98K +31 +0.1%
Asset Management One
96
Asset Management One
Japan
$1.44M +$1.11M +17,435 +487%
PA
97
Profund Advisors
Maryland
$1.42M -$7.72K -121 -0.6%
Allianz Asset Management
98
Allianz Asset Management
Germany
$1.39M +$1.25M +19,588 New
Squarepoint
99
Squarepoint
New York
$1.26M +$613K +9,600 +119%
Macquarie Group
100
Macquarie Group
Australia
$1.04M -$555K -8,700 -37%
2 3
4
5 6

RARE Hedge Fund Activity: Q3 2016 in Review

172 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2016, worth a combined $2.79B — up 54% from $1.81B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new RARE positions and 15 closed out — a net gain of 12 holders — while 67 added to existing stakes and 56 trimmed.

The largest buyer was Capital Guardian Trust, opening a new position worth an estimated $31.5M. The largest seller was Wells Fargo, cutting an estimated $39.1M.

  • 172 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2016, up from 161 in Q2 2016.
  • Funds reported $2.79B of Ultragenyx Pharmaceutical stock for Q3 2016, up 54% quarter-over-quarter.
  • 27 funds opened new Ultragenyx Pharmaceutical positions in Q3 2016 and 15 closed out, a net change of +12 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q3 2016 was Capital Guardian Trust, an estimated $31.5M added.
  • The largest Ultragenyx Pharmaceutical seller in Q3 2016 was Wells Fargo, an estimated $39.1M sold.

Based on aggregated 13F filings for Q3 2016.